Skip to library content
Back to the shelf
Peptide library
In clinical trialsDigestive & weight

Retatrutide

Also called LY3437943

Evidence
Extensive research
Class
Triple GLP-1 / GIP / glucagon agonist

Retatrutide belongs to the Triple GLP-1 / GIP / glucagon agonist class. This library groups it under digestive & weight. Its source category is In clinical trials.

Research libraryPeppy Care
Source snapshot
References11 linked sources

At a glance

Retatrutide research overview
Compound classTriple GLP-1 / GIP / glucagon agonist
Body systemDigestive & weight
Use or research focusObesity; type 2 diabetes; MASH
Regulatory statusInvestigational (Phase 3)
Source evidence ratingExtensive research

How does Retatrutide work?

'Triple-G' co-agonist for weight/glucose.

The source catalog maps this mechanism to Pancreas, Brain / CNS, Whole-body / Metabolic. A biological mechanism describes how a compound interacts with the body; it does not by itself prove a clinical benefit.

What does the evidence tell us?

The source catalog places this compound in its strongest research tier below approved-drug evidence. Study quality, population, outcomes, and follow-up still matter. A research rating alone does not establish that a treatment is appropriate for an individual.

Use the Citations tab to examine the underlying sources. Look for human studies, a relevant comparison group, meaningful outcomes, and adequate follow-up. An ingredient, approved drug, and compounded preparation may have different evidence.

Safety and considerations

A compound being studied in a clinical trial is not necessarily approved or effective. Trial participants follow a study protocol with eligibility criteria and monitoring. Results from one population or formulation may not apply to another.

This library is educational and does not provide dosing or treatment instructions. A listing here does not indicate that Peppy offers the compound.

Common questions

What is Retatrutide?

Retatrutide belongs to the Triple GLP-1 / GIP / glucagon agonist class. This library groups it under digestive & weight. Its source category is In clinical trials. Its recorded use or research focus is: Obesity; type 2 diabetes; MASH.

Is Retatrutide FDA-approved?

The catalog records: Investigational (Phase 3). Check the current product-specific regulatory information in the source links; a source category does not establish approval for every use or formulation.

How strong is the research?

The source catalog places this compound in its strongest research tier below approved-drug evidence. Study quality, population, outcomes, and follow-up still matter. A research rating alone does not establish that a treatment is appropriate for an individual.

Where can I read the research?

The Citations tab contains 11 reference links from the source dataset. The original research guide provides additional context. These links are a starting point for reading the evidence.

More for digestive & weight

Factual catalog fields and citation links are adapted from Superpower’s Retatrutide guide and the public dataset linked in the reference post. Peppy’s explanations are educational; this page does not represent an independent clinical review of every linked study.